AstraZeneca Pharma India Limited has informed the Exchange about General Updates

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

ASTRAZEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.2%Reaction day

₹9194.50

prior close

₹9195.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.2%-1.5% vs market

Pharmaceuticals peers, median of 149sector+0.5%-0.7% vs sector

On the reaction day the stock moved 1.5 pts less than Nifty Microcap 250 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.9

10m

+3.2

15m

+2.7

30m

+2.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.2+1.2-1.5+0.5-0.7

Next day

-0.2+1.7-1.9+0.8-1.0

+1.8+2.0-0.2+1.2+0.6

-1.1+1.4-2.6+0.8-1.9

-0.2+1.3-1.5+0.3-0.5

-2.1+1.2-3.3-0.1-2.0

-1.5+0.7-2.2+0.1-1.6

15d

-3.7-2.7-1.0-3.3-0.5

-8.5-3.4-5.1-4.2-4.3

-2.1-1.3-0.8-3.3+1.1

-0.6-3.7+3.1-6.3+5.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 149Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

AstraZeneca Pharma India has received permission from the Central Drugs Standard Control Organisation (CDSCO) to import and market Durvalumab Solution for Infusion (brand name Imfinzi) in 120 mg/2.4 ml and 500 mg/10 ml strengths for an additional indication. The approval covers Imfinzi in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi alone as adjuvant treatment after radical cystectomy, for adult patients with muscle invasive bladder cancer (MIBC). With this nod, the company can now market Imfinzi in India for this additional indication, subject to any further statutory approvals. The drug was already approved in India for other indications and is one of AstraZeneca's key oncology products globally.

Likely market impact

This expands the addressable market for Imfinzi in India by adding a new patient segment (muscle invasive bladder cancer), which could support future revenue growth in the oncology portfolio. It is a positive regulatory development but the company has not disclosed any expected financial impact at this stage.